26557-78-8

Basic information

• Product Name: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)
• Synonyms: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl);4-(prop-2-ynyloxy)aniline;4-Aminophenyl propargyl ether;4-(2-Propynyloxy)aniline;4-(2-Propyn-1-yloxy)benzenamine;4-Prop-2-ynyloxy-phenylamine;[4-(Prop-2-yn-1-yloxy)phenyl]amine hydrochloride
• CAS NO: 26557-78-8
• Molecular Formula: C₉H₉NO
• Molecular Weight: 183.64
• Mol File: 26557-78-8.mol
• Article Data: 41

Chemical Properties

• Melting Point: 52.0 to 56.0 °C
• Boiling Point: 95°C/10mmHg(lit.)
• Flash Point: >110℃
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.90±0.10(Predicted)
• CAS DataBase Reference: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)(26557-78-8)
• EPA Substance Registry System: 4-(2-propyn-1-yloxy)aniline(SALTDATA: HCl)(26557-78-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 26557-78-8(Hazardous Substances Data)

Usage

General Description

4-(2-propyn-1-yloxy)aniline, also known as propargyloxyaniline hydrochloride or affects 69036, is a chemical compound primarily used in scientific and industrial applications. It is characterized by a hydrogen chloride (HCl) salt form, indicating its potential acidic properties. Its specific structure consists of a propynyl group attached to an aniline group through an oxygen bridge in its 4th position. It is important to handle this chemical with care as it may pose certain hazards. Detailed properties such as its solubility, stability, and reactivity under different conditions are typically determined through rigorous testing and research. Potential applications could range from pharmaceuticals to polymer and material science depending on its discovered properties.

Upstream product

• 17061-85-7 1-nitro-4-(prop-2-ynyloxy)benzene 
• 54840-15-2 4-N-tert-butoxycarbonylaminophenol 
• 106-96-7 propargyl bromide 
• 54840-30-1 tert-butyl (4-(prop-2-yn-1-yloxy)phenyl)-carbamate 
• 123-30-8 4-amino-phenol 
• 26257-98-7 4-[2-(4-hydroxyphenyl)diazenyl]benzoic acid methyl ester 
• 103-90-2 4-acetaminophenol 
• 100-02-7 4-nitro-phenol 
• 1693-39-6 N-(4-hydroxyphenyl)formamide 
• 26557-77-7 N-(4-(prop-2-yn-1-yloxy)phenyl)acetamide 

Downstream Products

• 51857-93-3 (1,5-Dimethyl-hex-4-enyl)-(4-prop-2-ynyloxy-phenyl)-amine 
• 1561107-36-5 4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)aniline 
• 1561106-96-4 4-hydroxy-5-methyl-3-((4-(prop-2-ynyloxy)phenyl)diazenyl)-2H-pyran-2-one 
• 1561107-09-2 3-((4-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-4-hydroxy-5-methyl-2H-pyran-2-one 
• 1561107-15-0 6-((4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-17-2 6-((4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-20-7 6-((4-((1-(4-tolyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-benzo[d][1,3]dioxol-5-ol 
• 1561107-22-9 6-((4-((1-(4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-25-2 6-((4-((1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-28-5 6-((4-((1-(3-chloro-4-fluorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561107-31-0 6-((4-((1-(4-bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)benzo[d][1,3]dioxol-5-ol 
• 1561106-99-7 4-hydroxy-3-((4-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-5-methyl-2H-pyran-2-one 
• 1561107-01-4 4-hydroxy-5-methyl-3-((4-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-2H-pyran-2-one 
• 1561107-03-6 4-hydroxy-3-((4-((1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)diazenyl)-5-methyl-2H-pyran-2-one 

Relevant articles and documents

Divinylsulfonamides as Specific Linkers for Stapling Disulfide Bonds in Peptides

A new class of N-phenyl-divinylsulfonamides which can be easily prepared have been successfully developed and utilized as efficient linkers in the field of disulfide bond modification. Functional divinylsulfonamides provide opportunities for the specific

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

Structure–activity relationships of GPX4 inhibitor warheads

Direct inhibition of GPX4 requires covalent modification of the active-site selenocysteine. While phenotypic screening has revealed that activated alkyl chlorides and masked nitrile oxides can inhibit GPX4 covalently, a systematic assessment of potential electrophilic warheads with the capacity to inhibit cellular GPX4 has been lacking. Here, we survey more than 25 electrophilic warheads across several distinct GPX4-targeting scaffolds. We find that electrophiles with attenuated reactivity compared to chloroacetamides are unable to inhibit GPX4 despite the expected nucleophilicity of the selenocysteine residue. However, highly reactive propiolamides we uncover in this study can substitute for chloroacetamide and nitroisoxazole warheads in GPX4 inhibitors. Our observations suggest that electrophile masking strategies, including those we describe for propiolamide- and nitrile-oxide-based warheads, may be promising for the development of improved covalent GPX4 inhibitors.